Plural Hetero Rings Patents (Class 549/320)
  • Patent number: 9427425
    Abstract: The current disclosure discloses acetogenin(s), extract(s)/fraction(s) standardized to acetogenin(s) comprising terminal ?,?-unsaturated-?-methyl-?-lactone moiety derived from Annona squamosa or their compositions for prevention, treatment, inhibition or controlling inflammation and immune related diseases or disorders mediated through cytokines/chemokines or other biomarkers. The disclosure further discloses said Annona squamosa derived acetogenin(s), extract(s)/fraction(s) or their compositions for prevention, treatment, inhibition or controlling metabolic diseases/disorders.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: August 30, 2016
    Assignee: LAILA NUTRACEUTICALS
    Inventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Venkata Kanaka Ranga Raju Gokaraju, Trimurtulu Golakoti, Krishanu Sengupta, Kiran Bhupathiraju
  • Patent number: 9248156
    Abstract: The present invention is directed to the use of extracts or of extract compounds from Piper cubeba L. as active components in a medicament for the treatment of cancer. The invention also relates to a method for the preparation of a dry extract from the fruit of Piper cubeba L.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: February 2, 2016
    Assignee: Viridis Pharmaceutical Limited
    Inventors: Matthias-Heinrich Kreuter, Jian Ying Yam, Karin Berger-Buter
  • Patent number: 9056816
    Abstract: The present invention provides a novel process and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren, or a salt thereof, preferably Aliskiren hemifumarate.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: June 16, 2015
    Assignee: JUBILANT LIFE SCIENCES LIMITED
    Inventors: Sujay Biswas, Sankareswaran Srimurugan, Anjul Kumar, Atulya Kumar Panda, Danish Jamshad, Mukesh Masand, Bidyut Biswas, Vikas Bansal, Ashish Kumar Gupta, Dharam Vir
  • Publication number: 20150080349
    Abstract: The present invention provides compounds and methods for modulation of the quorum sensing of bacteria. In an embodiment, the compounds of the present invention are able to act as replacements for naturally occurring bacterial quorum sensing ligands in a ligand-protein binding system; that is, they imitate the effect of natural ligands and produce an agonistic effect. In another embodiment, the compounds of the present invention are able to act in a manner which disturbs or inhibits the naturally occurring ligand-protein binding system in quorum sensing bacteria; that is, they produce an antagonistic effect. The compounds of the present invention comprise N-acylated-homoserine lactones (AHLs) comprised of a wide range of acyl groups.
    Type: Application
    Filed: July 10, 2014
    Publication date: March 19, 2015
    Inventors: Helen E. BLACKWELL, Grant D. GESKE, Jennifer C. CAMPBELL
  • Publication number: 20140058021
    Abstract: A composition, which comprises a) an organic material susceptible to oxidative, thermal or light-induced degradation; and b) a compound of formula I (Formula I) (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are independently from each other H, C1-C8-alkyl, C4-C8-cycloalkyl, phenyl, C1-C4-alkoxy or halogen; n is 1, 2, 3, or 4; and when n is 1 A is —C(=0)-OR?1, —C(=0)-N(R?2)(R?3), —CN, phenyl, which is unsubstituted or substituted by one or more C1-C8-alkyl, C4-C8-alkoxy, C5-C7-cycloalkyl or halogen, —H or —S02-phenyl; when n is 2 A is —C(=0)-O—Z1—O—C(=0)-, —C(=0)-N(R?1)—Z2—N(R?2)—C(=0)- or piperazine-N,N?-biscarbonyl.
    Type: Application
    Filed: April 25, 2012
    Publication date: February 27, 2014
    Applicant: BASF SE
    Inventors: Walter Fischer, Abdel-Ilah Basbas, Kai-Uwe Schoning, Cinzia Tartarini, Werner Holzl, Bruno Rotzinger
  • Patent number: 8541606
    Abstract: A polymer compound for a photoresist composition (a) having a high dissolution rate in a developing solution after exposure and (b) exhibiting little swelling during development. A tertiary alcohol derivative that is a raw material for the polymer compound. A tertiary alcohol that is an intermediate of the tertiary alcohol derivative. The tertiary alcohol is represented by formula (3): wherein R1 and R2 individually represent a linear, branched or cyclic alkylene group having 2 to 9 carbon atoms, which may contain an oxygen atom, and wherein R1 and R2 may together form a ring with a carbon atom to which R1 and R2 are bonded.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: September 24, 2013
    Assignee: Kuraray Co., Ltd.
    Inventors: Takashi Fukumoto, Ichihiro Aratani
  • Publication number: 20130237711
    Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.
    Type: Application
    Filed: April 23, 2013
    Publication date: September 12, 2013
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Farid BENAYOUD, Trevor Lee Calkins, Charles E. Chase, William Christ, Francis G. Fang
  • Publication number: 20130028837
    Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.
    Type: Application
    Filed: August 10, 2012
    Publication date: January 31, 2013
    Applicant: Lantheus Medical Imaging, Inc.
    Inventors: Heike S. Radeke, David S. Casebier, Michael T. Azure, Douglas D. Dischino
  • Patent number: 8309743
    Abstract: The present invention provides a compound having absorbing and luminescence wavelengths at relatively longer wavelength side of the visible area, and having thermal stability, which acts as a dye and/or a luminescence material and has practical utility therefor, and a production method thereof.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: November 13, 2012
    Assignee: The University of Tokyo
    Inventors: Hiroshi Nishihara, Mikihiro Hayashi, Fumiyuki Toshimitsu
  • Patent number: 8212058
    Abstract: The present invention relates to a endothelin receptor antagonist conjugate of the formula (I) wherein R2 is an alkoxy group and one of R1 and R3 represents an alkoxy group and the other represents a group of the formula: (OCH2CH2)n—NH—X, wherein n is an integer of 1 to 100 and X represents a fluorescent dye and tautomers thereof. Furthermore, the present invention relates to a diagnostic composition comprising the compounds of the invention. The present invention also relates to the use of the compounds of the invention for the preparation of a diagnostic composition for the diagnosis of cancer, the evaluation of cancer biology and/or monitoring of anticancer therapy. In a further aspect, the present invention relates to kits comprising the compounds of the invention.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: July 3, 2012
    Assignee: Universitatskilinikum Munster
    Inventors: Christoph Bremer, Carsten Höltke, Klaus Kopka, Michael Schäfers
  • Publication number: 20120157677
    Abstract: The present invention relates to lactone compounds represented by the following Formulas I and II, and methods of making such lactone compounds. The present invention also relates to methods of making other materials from such lactone compounds, such as fused ring indenol compounds (e.g., indeno-fused naphthols), and fused ring indenopyran compounds (e.g., indeno-fused naphthopyrans).
    Type: Application
    Filed: December 7, 2011
    Publication date: June 21, 2012
    Applicant: TRANSITIONS OPTICAL INC.
    Inventors: Meng He, Darrin R. Dabideen, Ruisong Xu, Anil Kumar
  • Publication number: 20120149921
    Abstract: A polymer compound for a photoresist composition (a) having a high dissolution rate in a developing solution after exposure and (b) exhibiting little swelling during development. A tertiary alcohol derivative that is a raw material for the polymer compound. A tertiary alcohol that is an intermediate of the tertiary alcohol derivative. The tertiary alcohol is represented by formula (3): wherein R1 and R2 individually represent a linear, branched or cyclic alkylene group having 2 to 9 carbon atoms, which may contain an oxygen atom, and wherein R1 and R2 may together form a ring with a carbon atom to which R1 and R2 are bonded.
    Type: Application
    Filed: December 16, 2011
    Publication date: June 14, 2012
    Applicant: Kuraray Co., Ltd.
    Inventors: Takashi FUKUMOTO, Ichihiro Aratani
  • Publication number: 20120149886
    Abstract: The present disclosure provides systems for producing engineered oleaginous yeast or fungi that express carotenoids.
    Type: Application
    Filed: April 10, 2009
    Publication date: June 14, 2012
    Applicant: MICROBIA, INC.
    Inventors: Richard B. Bailey, Kevin T. Madden, Joshua Trueheart, Reed Doten, Maria Mayorga, Joshua Griffin Dunn, Dan Dueppen
  • Publication number: 20110185944
    Abstract: A novel chemical genus of furan-2-one antifouling compound as non-toxic, environment friendly antifouling agent, a coating material for objects submerged under the water based on the furan-2-one compounds. The substituted furan-2-one antifouling compounds have a furan-2-one ring and an alkyl side chain thereto and are of the formula: where n=6-14, representing the number of carbon atoms in said side chain.
    Type: Application
    Filed: April 16, 2009
    Publication date: August 4, 2011
    Inventors: Peiyuan Qian, Ying Xu, Xiaojian Zhou, Hongping He, Nobuhiro Fusetani, Wei-Min Dai
  • Patent number: 7927780
    Abstract: A compound represented by formula (I); and a compound represented by formula (b1-1): wherein X represents —O—, —S—, —O—R3— or —S—R4—, wherein each of R3 and R4 independently represents an alkylene group of 1 to 5 carbon atoms; R2 represents an alkyl group of 1 to 6 carbon atoms, an alkoxy group of 1 to 6 carbon atoms, a halogenated alkyl group of 1 to 6 carbon atoms, a halogen atom, a hydroxyalkyl group of 1 to 6 carbon atoms, a hydroxyl group or a cyano group; a represents an integer of 0 to 2; Q1 represents an alkylene group of 1 to 12 carbon atoms or a single bond; Y1 represents an alkylene group of 1 to 4 carbon atoms or a fluorinated alkylene group; M+ represents an alkali metal ion; and A+ represents an organic cation.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: April 19, 2011
    Assignee: Tokyo Ohka Kogyo Co., Ltd.
    Inventors: Akiya Kawaue, Takeshi Iwai, Hideo Hada, Shinichi Hidesaka, Tsuyoshi Kurosawa, Natsuko Maruyama, Kensuke Matsuzawa, Takehiro Seshimo, Hiroaki Shimizu, Tsuyoshi Nakamura
  • Publication number: 20110077416
    Abstract: The present invention provides a compound having absorbing and luminescence wavelengths at relatively longer wavelength side of the visible area, and having thermal stability, which acts as a dye and/or a luminescence material and has practical utility therefor, and a production method thereof.
    Type: Application
    Filed: March 12, 2010
    Publication date: March 31, 2011
    Applicant: THE UNIVERSITY OF TOKYO
    Inventors: Hiroshi Nishihara, Mikihiro Hayashi, Fumiyuki Toshimitsu
  • Patent number: 7862867
    Abstract: Disclosed is a bifunctional polymerizable compound represented by the formula [1]. Also disclosed is a polymerizable liquid crystal composition comprising at least one bifunctional polymerizable compound represented by the formula [1] and a polymerizable liquid crystal compound. The bifunctional polymerizable compound has a high polymerizability. When added to a polymerizable liquid crystal compound to prepare a polymerizable liquid crystal composition, the bifunctional polymerizable compound enables to remarkably improve the thermal stability of a polymer produced from the composition. The polymerizable liquid crystal composition containing the bifunctional polymerizable compound has a low crystallization temperature and shows a stable liquid-crystallinity under ordinary environment wherein X1, X2 and X3 independently represent a single bond or a benzene ring; Y represents —O— or a single bond; M represents a lactone ring or an acrylate group; and n represents an integer of 4 to 10.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: January 4, 2011
    Assignee: Nissan Chemical Industries, Ltd.
    Inventor: Daniel Antonio Sahade
  • Patent number: 7521569
    Abstract: The invention refers to a process to obtain lignans, especially to obtain cubebin and methylpluviatolide from leaves of Zanthoxylum naranjillo or Piper cubeba. It also refers to a process to obtain semi-synthetic derivatives of cubebin, especially dibenzylbutirloactonic lignans, such as: hinokinin, o-acetyl cubebin, o-methyl cubebin, 6, 6?-dinitrohinokinin and o-dimethylethylamine cubebin and other derivatives which may be obtained, as well as to obtain methylpluviatolide derivatives, which are used to manufacture drugs to provide activity at least five times higher than observed for gentian violet and other compounds used heretofore for blood treatment and Chagas' disease prophylaxis.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: April 21, 2009
    Assignee: Fundação De Amparo À Pesquisa Do Estado de São Paulo
    Inventors: Marcio Luis Andrade Silva, Sergio Albuquerque, Gustavo Henrique Bianco Souza, Jairo Kenupp Bastos, Rosangela Silva
  • Patent number: 7414139
    Abstract: The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substates for enzymes of the methionine sulfoxide reductase (Msr) class. Some embodiments of the catalytic antioxidant compounds are derived from drugs with anti-inflammatory activity due to inhibition of cyclooxygenase enzymes.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: August 19, 2008
    Assignees: Florida Atlantic University, Hosptial for Special Surgery
    Inventors: Herbert Weissbach, Nathan Brot
  • Patent number: 7341818
    Abstract: The disclosed invention relates to novel norborne-type monomers containing pendent lactone or sultone groups. The invention also relates to norborne-type polymers and copolymers containing pendent lactone or sultone groups. These polymers and copolymers are useful in making photoimagable materials. The photoimagable materials are particularly suitable for use in photoresist compositions useful in 193 and 157 nm photolithography.
    Type: Grant
    Filed: January 10, 2005
    Date of Patent: March 11, 2008
    Assignee: Promerus LLC
    Inventors: Xiaoming Wu, Larry F. Rhodes, Lawrence Seger
  • Patent number: 7317114
    Abstract: The invention refers to a process to obtain lignans, especially to obtain cubebin and methylpluviatolide from leaves of Zanthoxylum naranjillo or Piper cubeba. It also refers to a process to obtain semi-synthetic derivatives of cubebin, especially dibenzylbutirloactonic lignans, such as: hinokinin, o-acetyl cubebin, o-methyl cubebin, 6,6?-dinitrohinokinine and o-dimethylethylamine cubebin and other derivatives which may be obtained, as well as to obtain methylpluviatolide derivatives, which are used to manufacture drugs to provide activity at least five times higher than observed for gentian violet and other compounds used heretofore for blood treatment and Chagas' disease prophylaxis.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: January 8, 2008
    Assignee: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
    Inventors: Márcio Luis Andrade Silva, Sérgio Albuquerque, Gustavo Henrique Bianco Souza, Jairo Kenupp Bastos, Rosângela Silva
  • Patent number: 7223792
    Abstract: Acetogenins isolated from Annona muricata of the family Annonaceae are described. The substantially pure compounds of the invention exhibit to human tumor cell lines as well as selective cytotoxicity for various human tumor cell lines.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: May 29, 2007
    Assignees: Advpharma Inc.
    Inventor: Yang-Chang Wu
  • Patent number: 7101654
    Abstract: The disclosed invention relates to novel norbornene-type monomers containing pendent lactone or sultone groups. The invention also relates to norbornene-type polymers and copolymers comprising one or more repeating units represented by the formula: and containing pendent lactone or sultone groups. These polymers and copolymers are useful in making photoimagable materials. The photoimagable materials are particularly suitable for use in photoresist compositions useful in 193 and 157 nm photolithography.
    Type: Grant
    Filed: January 14, 2004
    Date of Patent: September 5, 2006
    Assignee: Promerus LLC
    Inventors: Xiaoming Wu, Larry F. Rhodes, Lawrence Seger
  • Patent number: 6833460
    Abstract: The rate of aminolysis of butyrolactones is predictably adjusted by attaching a substituent having a known field effect value (F) to the alpha position before reacting the substituted buytrolactone with an amine. The aminolysis product is a gamma-hydroxy amide. The resulting materials are useful as the cross-linking agents in a variety of coatings and coatings processes.
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: December 21, 2004
    Assignee: E. I. du Pont de Nemours and Company
    Inventor: Albert Gordon Anderson
  • Publication number: 20040209778
    Abstract: The invention provides a lactone derivative of formula (I) which exhibits excellent rooting activity, and a plant growth regulator containing the derivative as an active ingredient.
    Type: Application
    Filed: February 20, 2004
    Publication date: October 21, 2004
    Inventors: Koji Kobayashi, Mineyuki Yokoyama
  • Publication number: 20040171677
    Abstract: The invention relates to substituted &ggr;-lactone compounds, to methods for the production thereof, to medicaments containing these compounds and to the use of these compounds for producing medicaments.
    Type: Application
    Filed: January 5, 2004
    Publication date: September 2, 2004
    Inventors: Corinna Sundermann, Michael Przewosny, Werner Englberger
  • Patent number: 6713507
    Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: March 30, 2004
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Patent number: 6703422
    Abstract: The present invention relates to novel sulfide and disulfide compounds, compositions comprising sulfide and disulfide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: March 9, 2004
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Patent number: 6699910
    Abstract: The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: March 2, 2004
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Publication number: 20040014993
    Abstract: The present invention relates to a novel process for the preparation of optically enriched substituted R(+)&bgr;-benzyl-&ggr;-butyrolactones of the general formula 1, 1
    Type: Application
    Filed: March 3, 2003
    Publication date: January 22, 2004
    Applicant: Council of Scientific and Industrial Research
    Inventors: Subhash Chandra Taneja, Surrinder Kaul, Buddh Singh, Ghulam Nabi Qazi
  • Patent number: 6673780
    Abstract: The present invention relates to novel sulfoxide and bis-sulfoxide compounds, compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: January 6, 2004
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Publication number: 20030166684
    Abstract: The invention concerns a compound of formula (I), wherein, for example: R1 is of the formula —NHC(═O)(1-4C)alkyl; R2 and R3 are hydrogen or fluoro; R4 and R5 are hydrogen or methyl; >A-B- is of the formula >C═CH—, >CHCH2, or >C(OH)CH2—(> represents two single bonds); D is O, S, SO, SO2 or —NR7; wherein R7 is hydrogen, R10CO—, R10SO2—, RaOC(Rb)═CH(C═O)—, RcC(═O)C(═O)—, RdN═C(Re)C(═O)—, RfNHC(Rg)═CHC(═O)— or R14CH(R13)(CH2)m—; wherein R10 is (1-6C)alkyl [optionally substituted by, for example, hydroxy or (1-6C)alkanoyl], R11C(O)O(1-6C)alkyl or R12O—; wherein R11 is optionally substituted (1-6C)alkyl; R12 is optionally substituted (1-6C)alkyl; Ra, Rb, Rc, Rd, Re, Rf, Rg are (1-6)alkyl; m is 0 or 1; R13 is cyano; R14 is hydrogen or (1-4C)alkyl; >X—Y— is of the formula >C═CH— or >CHCH2—; and pharmaceutically acceptable salts thereof
    Type: Application
    Filed: December 17, 2001
    Publication date: September 4, 2003
    Inventor: Michael Barry Gravestock
  • Publication number: 20030144348
    Abstract: Acetogenins isolated from Annona muricata of the family Annonaceae are described. The substantially pure compounds of the invention exhibit to human tumor cell lines as well as selective cytotoxicity for various human tumor cell lines.
    Type: Application
    Filed: December 7, 2001
    Publication date: July 31, 2003
    Inventor: Yang-Chang Wu
  • Publication number: 20030050336
    Abstract: The invention relates to a novel compound isosquamocin obtained from the plant Annona squamosa; also provides insecticidal compositions containing isosquamocin, squamocin-B (9), squamocin-C (6), squamocin-G (2), squamocin-H (3), squamocin-J (7), squamocin-K (8), squamocin-L (5), squamocin-M (4), squamostatin-A (10), bullatalicin (11), bullatanocin (12) and three unidentified related compounds with retention times 5.88,14.18 and 45.25 min. in HPLC obtained from the plant Annona squamosa and a process for the preparation of the novel compound and the insecticidal composition.
    Type: Application
    Filed: March 28, 2002
    Publication date: March 13, 2003
    Inventors: Akella Venkata Bhavani Shankaram, Madugula Marthanda Murthy, Dattatreya Manohar Akkewar, Mukkamala Subramanyam, Attaluri Narasimha Rao
  • Publication number: 20030022865
    Abstract: The present invention relates to novel sulfoxide and bis-sulfoxide compounds, compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    Type: Application
    Filed: October 11, 2001
    Publication date: January 30, 2003
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Publication number: 20030008232
    Abstract: (Meth)acrylate compounds having a norbornane, bicyclo[2.2.2]octane, 7-oxanorbornane or cyclohexane ring structure and a &ggr;-butyrolactone ring structure connected together by a suitable linker are novel and useful in forming polymers having high transparency, especially at the exposure wavelength of an excimer laser.
    Type: Application
    Filed: June 13, 2002
    Publication date: January 9, 2003
    Applicant: Shin-Etsu Chemical Co., Ltd.
    Inventors: Takeshi Kinsho, Koji Hasegawa, Takeru Watanabe
  • Publication number: 20020143195
    Abstract: This invention pertains to a process for making &agr;-methylenelactones and &agr;-substituted hydrocarbylidene lactones. More specifically, the present invention obtains high yields of &agr;-methylene-&ggr;-butyrolactone by heating &ggr;-butyrolactone and diethyl oxalate in the presence of a base. The second step comprises treatment of the &agr;-oxalyl enolate salt with formaldehyde to afford the &agr;-methylene-&ggr;-butyrolactone.
    Type: Application
    Filed: December 21, 2001
    Publication date: October 3, 2002
    Inventors: Rutger D. Puts, Charles Brandenburg, Kenneth R. Tarburton
  • Patent number: 6423850
    Abstract: The rate of aminolysis of butyrolactones is predictably adjusted by attaching a substituent having a known field effect value (F) to the alpha position before reacting the substituted buytrolactone with an amine. The aminolysis product is a gamma-hydroxy amide. The resulting materials are useful as the cross-linking agents in a variety of coatings and coatings processes.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: July 23, 2002
    Assignee: E.I. du Pont de Nemours and Company
    Inventor: Albert Gordon Anderson
  • Patent number: 6410590
    Abstract: The present invention relates to novel derivatives of Andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The novel derivatives of Andrographolide have the general formula (I) The andrographolide derivatives represented by general formula (I) are useful for treating cancer, HSV, HIV, psoriasis, restonosis, atherosclerosis, other cardiovascular disorders, and can be used as antiviral, antimalarial, antibacterial, hepatoprotective, and immunomodulating agents and for treatment of other metabolic disorders.
    Type: Grant
    Filed: February 1, 2001
    Date of Patent: June 25, 2002
    Assignee: Dr. Reddy's Research Foundation
    Inventors: Srinivas Nanduri, Sriram Rajagopal, Sairam Pothukuchi, Sunilkumar Bhadramma Kochunarayana Pillai, Ranjan Chakrabarti
  • Patent number: 6350775
    Abstract: A compound of formula (I): wherein R1 is hydroxy or of the formula —NHC(═O)(1-4C)alkyl or —NHS(O)n(1-4C)alkyl wherein n is 0, 1 or 2; R2 and R3 are independently hydrogen or fluoro; R4 and R5 are independently hydrogen or methyl; >A—B— is of the formula >C═CH—, or >C(OH)CH2—; >X—Y— is of the formula >C=CH—, or >CHCH2—; and D is S, SO, or SO2; or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: July 24, 2000
    Date of Patent: February 26, 2002
    Assignee: Zeneca Limited
    Inventor: Michael Barry Gravestock
  • Patent number: 6306899
    Abstract: This invention relates to anti-viral drugs such as Helioxanthin and its analogs. The present compounds may be used alone or in combination with other drugs for the treatment of Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever, Dengue Virus, Japanese Encephalitis, West Nile virus and related flaviviruses. In addition, compounds according to the present invention can be used to prevent hepatoma secondary to virus infection as well as other infections or disease states which are secondary to the virus infection.
    Type: Grant
    Filed: August 23, 1999
    Date of Patent: October 23, 2001
    Assignees: Yale University, N. Y. Mu, N.T.U., V.G.H
    Inventors: Yung-Chi Cheng, Chen-Kung Chou, Lei Fu, Yueh-Hsiung Kuo, Sheau-Farn Yeh, Juliang Zhu, Yonglian Zhu
  • Patent number: 6297274
    Abstract: Novel nonpeptide endothelin I antagonists of Formula are described wherein R1 is unsubstituted or substituted cycloalkyl, phenyl, naphthyl or heteroaryl, R2 is unsubstituted or substituted alkyl, aryl or heteroaryl, R3 is unsubstituted or substituted alkyl, cycloalkyl, aryl or heteroayl, and R1 and/or R2 and/or R3 are independently substituted by a total of from 1 to 4 substituents which enhance aqueous solubility with the proviso that when R2 is alkyl and is substituted, the substituent is not oxygen at the &agr;-position of the furanone ring.
    Type: Grant
    Filed: August 4, 1998
    Date of Patent: October 2, 2001
    Assignee: Warner-Lambert Company
    Inventors: Xue-Min Cheng, Annette Marian Doherty, William Chester Patt, Joseph Thomas Repine
  • Patent number: 6242483
    Abstract: The isolation of three new mono-tetrahydrofuran ring acetogenins from the bark of Annona squamosa is described. Each of these compounds bears a carbonyl group at the C-9 position and two hydroxyls that flank the tetrahydrofuran ring. These compounds exibit selective cytotoxic activity against certain specific human tumor cells.
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: June 5, 2001
    Assignee: Purdue Research Foundation
    Inventors: Jerry L. McLaughlin, David Craig Hopp
  • Patent number: 6222048
    Abstract: The invention encompasses the novel compound of Formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula (I). The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).
    Type: Grant
    Filed: June 12, 1997
    Date of Patent: April 24, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Cameron Black, Erich Grimm, Serge Leger, Petpiboon Prasit, Zhaoyin Wang
  • Patent number: 6160004
    Abstract: The present invention provides a two-step procedure for the replacement of the pyranose anomeric 10-OH group in dihydroartemisinin by a variety of carbon nucleophiles, resulting in the novel C-10 carbon-substituted trioxanes of structure: ##STR1## wherein, when n is 1, R is selected from a group of unsubstituted or substituted aryls, heteroaryls, polyethylene glycol, acetylenics, or benzoylmethylenes, or alkanoylmethylenes; or when n is 2, R is selected from a group of unsubstituted or substituted aryls, heteroaryls, polyethylene glycol, alkenyls, alkyls, diketones or bis-acetylenes; or when n is 3, R is selected from a group of unsubstituted or substituted aryls, heteroaryls, polyethylene glycol, alkenyls, alkyls, diketones or bis-acetylenes.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: December 12, 2000
    Assignees: Hauser, Inc., Johns Hopkins University
    Inventors: Gary H. Posner, Soon Hyung Woo, Poonsakdi Ploypradith, Michael H. Parker, Theresa A. Shapiro, Jeffrey S. Elias, John Northrop, Qun Y. Zheng, Christopher Murray, Randall J. Daughenbaugh
  • Patent number: 6037365
    Abstract: This invention provides a compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutical compositions of such compounds and a method of treatment to inhibit aggregation of platelets.
    Type: Grant
    Filed: September 25, 1998
    Date of Patent: March 14, 2000
    Assignee: G.D. Searle & Co.
    Inventors: Philippe Roger Bovy, Joseph Gerace Rico, Thomas Edward Rogers
  • Patent number: 5998468
    Abstract: Novel nonpeptide antagonists of endothelin (I) are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cerebral ischemia, cerebral infarction, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, stroke, benign prostatic hyperplasia (BPH), and diabetes.
    Type: Grant
    Filed: December 15, 1997
    Date of Patent: December 7, 1999
    Assignee: Warner-Lambert Company
    Inventors: Xue-Min Cheng, Annette Marian Doherty, William Chester Patt, Joseph Thomas Repine
  • Patent number: 5972237
    Abstract: Heterocyclic compounds IR.sup.1 --X--L (I)whereL is a cyclic carbamate residue, a lactonoxy residue or a lactam residue,X is an oxygen-containing group ##STR1## where A is a linker, and R.sup.1 is an organic radical or a group L,are used as activators for inorganic peroxy compounds, in particular as cold bleach activators or optical brighteners in detergents, cleaners and bleaches and in disinfectants.
    Type: Grant
    Filed: November 17, 1997
    Date of Patent: October 26, 1999
    Assignee: BASF Aktiengesellschaft
    Inventors: Reinhard Muller, Thomas Wehlage, Wolfgang Trieselt, Alfred Oftring, Elisabeth Kappes, Gunter Oetter, Dieter Boeckh, Roland Ettl, Albert Hettche
  • Patent number: 5955497
    Abstract: Novel acetogenins isolated from Annona squamosa of the family Annonaceae are described. The substantially pure acetogenins of the invention exhibit cytotoxicity to human tumor cell lines as well as selective cytotoxicity for various human tumor cell lines.
    Type: Grant
    Filed: February 24, 1998
    Date of Patent: September 21, 1999
    Assignee: Purdue Research Foundation
    Inventors: Jerry L. McLaughlin, David C. Hopp
  • Patent number: 5919952
    Abstract: (-)-Swainsonine may be prepared by (i) reacting a compound of formula (8): ##STR1## wherein OMs is methanesulfonyl with H.sub.2 in the presence of Pd(OH).sub.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: July 6, 1999
    Assignee: The Regents of the University of Michigan
    Inventors: William H. Pearson, Erik J. Hembre